Nurix (NRIX) CSO Gwenn Hansen Exercises Options, Sells Shares

What Happened
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), exercised 4,356 stock options (exercise price $1.86) on Aug 5, 2026 for a cost of $8,102, and sold those 4,356 shares in an open-market transaction at $25.00 per share for gross proceeds of $108,900. The filing shows the option exercise and the subsequent sale on the same date.

Key Details

• Transaction date: 2026-08-05
• Exercise: 4,356 shares at $1.86 per share (total cost $8,102) — reported as code M (option exercise/conversion)
• Sale: 4,356 shares at $25.00 per share (gross proceeds $108,900) — reported as code S (sale)
• Filing notes: Transaction effected pursuant to a Rule 10b5-1 trading plan (footnote F1)
• Vesting: Option vested monthly (1/48) from June 10, 2019 and was fully vested May 10, 2023 (footnote F2)
• Shares owned after transaction: not specified in the filing
• Timeliness: Report shows transaction and filing date as Aug 5, 2026 — no late filing indicated

Context
This was an exercise of vested options followed by an immediate open-market sale — a common pattern where executives monetize vested equity. The 10b5-1 plan note indicates the sale was executed under a pre-established trading plan, which can limit claims of opportunistic timing. The filing does not, by itself, indicate the insider’s view of the company’s prospects.